Novel agent in gastroenteropancreatic neuroendocrine tumor

neuroendocrin tumors are a diverse group of tumors driven from epithelial cells with neuroendocrine differentation gastroenteropancreatic neuroendocrine tumors are a subset of the net that arises in the gastrointestinal tract and neuroendocrine tumor are the second most prevalent advanced GI cancer after colorectal cancer. treatment of advanced and metastatic gastroenteropancreatic nets has traditionally been difficult with few systemic treatment options. in 2011, two new targeted therapies, everolimus, and sunitinib were approved for the treatment of pancreatic net leading to increased interest in novel agents active in gastroenteropancreatic netsSSA has clear role in the treatment of symptoms related to hormone secretion in functional nets.octreotide and lanerotide have a role in tumor cytostatic controltargeted drugs single and combined therapies (sunitinib and mTOR inhibitors) have been tested in clinical trials.cytotoxic chemotherapy is typically used in necs and nets of higher tumor grade, heavy tumor burden and /or a more aggressive clinical course.over the years a role for both alkylating (streptozocin and temozolomide and dacarbazine) and platinum chemotherapy drug has been demonstrated primarily in pnet radiolabeled ssAs a form of peptide receptor radionuclide therapy (PRRT), has emerged as an effective option for patients with SSTR_expressing tumor.the first generation radionuclide used in PRRT was indium 111_agamma_emiting isotope subsequent generation of radionuclide isotope subsequent generation of radionuclide isotope is Y-90 and lut170.choice of therapy for net depends on several factors such as functional status, avidity on SSTR imaging and tumor pathologic grade and dx bulk and dx behavior